634198-01-9

Basic information

• Product Name: 5-Benzyloxy-4-Methoxy-2-nitro-benzoic acid benzyl ester
• Synonyms: 5-Benzyloxy-4-Methoxy-2-nitro-benzoic acid benzyl ester;BENZYL 5-(BENZYLOXY)-4-METHOXY-2-NITROBENZOATE
• CAS NO: 634198-01-9
• Molecular Formula: C₂₂H₁₉NO₆
• Molecular Weight: 393.38936
• Mol File: 634198-01-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Benzyloxy-4-Methoxy-2-nitro-benzoic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Benzyloxy-4-Methoxy-2-nitro-benzoic acid benzyl ester(634198-01-9)
• EPA Substance Registry System: 5-Benzyloxy-4-Methoxy-2-nitro-benzoic acid benzyl ester(634198-01-9)

Safety Data

• Hazardous Substances Data: 634198-01-9(Hazardous Substances Data)

Upstream product

• 645-08-9 Isovanillic acid 
• 100-39-0 benzyl bromide 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 148235-40-9 3-benzyloxy-4-methoxybenzoic acid benzyl ester 

Downstream Products

• 1638151-52-6 (R)-2-((7-methoxy-4-(3-(quinoxaline-2-yloxy)-pyrrolidine-1-yl)-quinazoline-6-yl)-oxy)ethyl 4-methylbenzenesulphonate 
• 911418-43-4 6-hydroxy-7-methoxy-2-(3-nitrophenyl)quinazolin-4(3H)-one 
• 911418-45-6 6-(benzyloxy)-7-methoxy-2-(3-nitrophenyl)quinazolin-4(3H)-one 
• 911418-44-5 4-methoxy-5-benzyloxy-2-(3-nitrobenzoylamino)benzamide 
• 60547-93-5 4-methoxy-5-benzyloxy-2-nitrobenzamide 
• 60547-95-7 4-methoxy-5-benzyloxy-2-aminobenzamide 
• 60564-37-6 5-benzyloxy-4-methoxy-2-nitrobenzoic acid 
• 634197-88-9 4-(6-benzyloxy-7-methoxy-quinazolin-4-yl)-piperazine-1-carboxylic acid (4-cyano-phenyl)-amide 
• 634197-93-6 {4-[4-(4-cyano-phenylcarbamoyl)-piperazin-1-yl]-7-methoxy-quinazolin-6-yloxy}-acetic acid methyl ester 
• 205259-46-7 4-(6-benzyloxy-7-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester 

Relevant articles and documents

PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

RHO KINASE INHIBITORS

The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.

PHARMACOKINETICALLY IMPROVED COMPOUNDS

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.